FindTrial
Sign In

A follow-up study for infliximab or combine with azathioprine in the treatment of Crohn's disease

Infliximab or combine with azathioprine in the treatment of Crohn's disease and relationship with ATI

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800020305
Enrollment
Unknown
Registered
2018-12-23
Start date
2016-01-01
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

crohn's disease

Interventions

Group 2:infliximab + azathioprine
Group 1:infliximab alone

Sponsors

Department of Gastroenterology, Nanfang Hospital, Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. CD under combination therapy with IFX and AZA or IFX alone for at least 6 months; 2. scheduled IFX treatment at a dose of 5 mg/kg at week 0,2,6,14, 22, 30 weeks and test TRL, ATI ,TNF-a at week 14 before the fourth time of IFX infusion; 3. AZA treatment should be concomitant with IFX at a dose of 2mg/kg; 4. after 6 times of IFX infusion, continuation of scheduled IFX treatment every 8 weeks or AZA everyday or both of them.

Exclusion criteria

Exclusion criteria: 1. The patient discontinues treatment for various reasons, stops treatment or refuses to receive relevant treatment or receives other treatments; 2. Other diseases occur during treatment and are not related to Crohn's disease, may affect treatment; 3. Unable to complete the follow-up.

Design outcomes

Primary

MeasureTime frame
antibody to infliximab;—

Countries

China

Contacts

Public ContactAimin Li

Nanfang Hospital, Southern Medical University

lam0725@qq.com+86 13580317630

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026